Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors

Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2019. POSTER


Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors

Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2018. Poster


Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors.

Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors. ASCO 2018. Poster


Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results

Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results. ESMO 2017. Poster


SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) With Broad and Potent Anti-Cancer Activity.

SL-801, a novel, reversible inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with broad and potent anti-cancer activity. ASH 2015. Poster